Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics.
Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics. Some topics he touches on include; what makes a good RNA construct; making RNA more tolerable; storage and distribution of lipid nanoparticles; and more.
For more INTERPHEX 2023 video content, check this page for updates.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.